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1. Introduction 
Allogeneic hematopoietic cell transplantation emerges as a therapy option to treat the 
sequels of exposure to radiation, a great concern at the beginning of the atomic age and cold 
war (Welniak et al., 2007). Hematopoietic cell transplantation emerged as a rescue strategy 
since there were already antecedents, like the study of Lorenz et al. in 1952 (as cited by 
Welniak et al., 2007), who showed that infusion of the bone marrow after lethal irradiation 
healed radiation disease in mice. This lay the foundations for the current consideration of 
allogeneic hematopoietic cell transplantation as the first-line therapy for many life-
threatening oncological and hematological diseases. Today, it is primarily used to treat 
patients with hereditary anemias or immunological deficiencies through replacement of the 
hematopoietic system with cells from a healthy individual. It also allows cancer patients to 
be treated with myeloablative radiation and/or chemotherapy (known as myeloablative 
conditioning) in an attempt to eliminate tumoral cells, and although this strategy brings loss 
of bone marrow function, the latter can be recovered with infusion of normal hematopoietic 
cells (Jenq & Van den Brink, 2010). 
2. Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation is today a simple procedure involving infusion of 
these cells intravenously. Once in the bloodstream, stem cells are able to migrate to the bone 
marrow in order to thus restore hematopoiesis during the first two weeks following 
transplantation (Léger & Nevill, 2004). 
Stem cells giving rise to hematopoietic cells are known as hematopoietic stem cells due to 
their capacity for self-renewal, division and differentiation into a variety of specialized 
hematopoietic cells. This is the principle underlying hematopoietic stem cell transplantation 
(Hows, 2005). 
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One of the major difficulties in using hematopoietic stem cells has been their identification, 
since they are morphologically very similar to lymphocytes. This problem was solved with 
the use of biomarkers such as CD34, a transmembrane glycoprotein expressed by 
hematopoietic stem cells which is currently the main biomarker used to identify these cells. 
Hematopoietic cell transplantations are classified as isotransplantation, allotransplantation 
or autotransplantation. These are not the only types of transplantation, but they are the most 
commonly used in medical practice. It calls allotransplantation when donor and recipient 
are the same species but are not identical twins. The advantages of this type of 
transplantation compared to the allogeneic type are that the cells infused are normal cells 
and therefore the incidence of relapse is lower, as well as the fact that the graft cell is infused 
with immunocompetent cells that are able to induce a graft-versus-leukemia effect. The 
major concern with this type of transplantation is development of graft-versus-host disease 
(GVHD) or infections caused by opportunistic microorganisms, since patients are treated 
with immunosuppressant drugs (Léger & Neville, 2004; Vela-Ojeda et al., 2005). 
2.1 Hematopoietic stem cell mobilization by G-CSF 
At present peripheral blood hematopoietic stem cells are preferably used since grafting 
(particularly of blood platelets) is faster. This procedure is not excessively invasive – as is 
bone marrow procurement – and better results are obtained when mobilized peripheral 
blood is used as the hematopoietic stem cells source (Jaime et al., 2004). Normally, 
peripheral blood contains only a small amount of hematopoietic stem cells (<0.1% of 
nucleated cells). Different methods are therefore used to induce their egress from the bone 
marrow into the bloodstream in order to be able to collect them by apheresis for subsequent 
infusion in the patient. Hematopoietic stem cells mobilization was an innovative 
development in the 1990s, in particular after it was seen that the number of stem cells 
obtained from mobilized peripheral blood contained 1-log more lymphocytes than the 
number obtained from bone marrow (Champlin, 2000). The established, widely-used 
method of mobilization involves the use of G-CSF, which induces mobilization by initiating 
a stress process through neutrophil and osteoclast activation. This results in dissociation of 
the cell membrane unions between stem cells and the stroma cells as well as stem cell 
proliferation and activation and/or adhesion molecule degradation. Hematopoietic stem 
cells mobilization is also seen when chemotherapy is exclusively used (Devetten & 
Armitage, 2007). 
The mechanism through which G-CSF mobilizes CD34+ hematopoietic stem cells from the 
bone marrow into the peripheral blood involves a series of steps. First of all, there is 
increased hematopoietic stem cell proliferation followed by exit of these cells from the bone 
marrow. Increased proliferation has been shown to occur with cytokines such as GM-CSF 
that temporarily increase the cell adhesion of CD34+ hematopoietic stem cells to the bone 
marrow stroma, a process that in turn increases cell proliferation. The mobilization of 
hematopoietic stem cells from the bone marrow to peripheral blood comprises several 
mechanisms. One hypothesis is modification of the cellular interactions occurring between 
hematopoietic stem cells and the bone marrow stroma. Analyses of peripheral blood 
mononuclear cells mobilized by G-CSF reveal a decrease in the expression of VLA-4 (Very 
late antigen 4 [CD49d/CD29]) integrin which normally binds firmly to its ligand VCAM-1 
(Vascular cell adhesion molecule-1) as well as to an extracellular-matrix fibronectine fragment. 
Other molecules in which a marked decrease occurs are LFA-1 (Leucocyte functional antigen 1 
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[CD11aCD18]) and c-kit. These molecules are expressed in most hematopoietic stem cells 
and are involved in binding of these cells to bone marrow stroma, a process that is 
expressed by the ligands of cells of the latter VCAM-1, ICAM-1 (Intercellular adhesion 
molecule-1) and ICAM-2 for LFA-1 and c-kitL. G-CSF can also initiate mobilization through 
neutrophils, by secretion of gelatinase B, breaking extracellular matrix molecules and  
 
 
Fig. 1. Mechanism of hematopoietic stem cell mobilization from bone marrow to peripheral 
blood by stimulation with G-CSF. This process involves several steps, including 
modification of interactions occurring between stem cells and the stroma. Affected 
interactions include decreased expression of VLA-4 integrin, which normally binds to its 
ligand VCAM-1 and to FNT. Another molecule in which expression is decreased is c-kit; this 
process reduces the bond between this molecule and its ligand kit-L-. Decreased expression 
of these molecules reduces the bond between stem cells and the stromal cells. Another 
means by which G-CSF promotes stem cell mobilization is through neutrophils, by releasing 
gelatinase B, breaking extracellular matrix molecules and weakening adhesive interactions 
between stem cells and stroma cells. Yet another mechanism is stem cell secretion of 
gelatinase B, promoting faster migration of these cells to peripheral blood. A further 
mechanism involves indirect interaction of G-CSF with ligands, receptors/factors and 
stimulation of stem cell proliferation. PB: peripheral blood. G-CSF: granulocytic-colony 
stimulating factor. VCAM-1: vascular cell adhesion molecule-1, VLA-4: very late antigen 4 
[CD49d/CD29] FNT: fibronectina (Modified from Gyger et al., 2000) 
www.intechopen.com
 
New Advances in Stem Cell Transplantation 
 
86
weakening adhesive interactions between stem cells and stroma cells. Stem cells have also 
been shown to secrete gelatinase B, a mechanism which may improve migration of these 
cells to peripheral blood (Figure 1). Finally, experimental evidence indicates that G-CSF may 
interact indirectly with a stem cell ligand to stimulate proliferation of these cells (Cashen et 
al., 2007; Cottler-Fox et al., 2003; Gyger et al., 2000). 
In recent years, it has been demonstrated that G-CSF is also able to break one of the most 
important interactions between stem cells and stromal cells, which is formed by CXCL12 
(formerly called SDF-1) and CXCR4 (Cashen et al., 2007). 
2.1.1 Which stem cell source is best: bone marrow or mobilized peripheral blood? 
This is one of the most commonly asked questions, since using mobilized peripheral blood 
rather than bone marrow in allogeneic transplantation is increasingly frequent. A 
retrospective study by Champlin et al. in 2000 examined the evolution of 288 allogeneic 
transplants in which mobilized peripheral blood was used and 536 in which bone marrow 
was used. They were followed-up during one year. The study found that in patients who 
had received mobilized peripheral blood, neutrophil engraftment was faster (14 days vs. 19) 
as was also platelet engraftment (19 days vs. 25). No significant differences were observed in 
development of acute GVHD. Chronic GVHD development was significantly higher in 
patients receiving mobilized blood, with a mean of 65% vs. 53%. The incidence of relapse 
did not differ significantly. Treatment-related mortality and leukemia-free survival were 
higher with mobilized blood transplants and hospitalization time was shorter. Additional 
studies similar to this one examining the benefits and drawbacks of allogeneic 
hematopoietic cell transplantation set the basis for mobilized peripheral blood being 
currently the most commonly used source in hematopoietic stem cell transplantation. 
2.2 Points to consider before hematopoietic stem cell transplantation 
When considering transplantation in patients in remission, two important aspects should be 
taken into account: whether medical evidence indicates that hematopoietic stem cells 
transplantation is more likely to heal the disease than other therapy forms and whether a 
suitable donor is available as a stem cell source. Although these are the major aspects to 
consider they are not the only ones. Other factors requiring consideration include biological 
characteristics at diagnosis, the specific disease that is being treated, presence of 
comorbidities that may complicate transplantation, and patient age (Deeg, 2010; Léger & 
Nevill, 2004). 
2.3 Immunological typing of human leukocyte antigens 
One reason for the progress that has taken place in hematopoietic cell transplantation is 
human leukocyte antigen (HLA) immunotyping. This is one of the major points to consider 
in allogeneic hematopoietic cell transplantation since, as already stated, it is important to 
have a suitable donor. 
HLA proteins were first identified in 1950 by Jean Dausset upon observing that in many 
individuals, particularly those who previously received multiple blood transfusions or who 
were multiparous women, blood serum contained antibodies that reacted against a new 
kind of glycoprotein present on the outer surface of leukocytes of other members of the 
population; these glycoproteins were named human leukocyte antigens (HLAs). The latter 
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behave as immunogenic markers making a person’s cells distinct and are the major barrier 
to histocompatibility; they are therefore also called major histocompatibility complex (MHC) 
molecules. The importance of HLA molecules is not limited to the histocompatibility barrier, 
they are also essential in T-cell activation since HLA-molecules bind peptides to be 
presented to T cells. HLA class I molecules present peptides primarily to CD8+ T cells while 
CD4+ T cells recognize mainly peptides presented by class II molecules (Appelbaum, 2001; 
Bleakley & Riddell, 2004). 
MHC genes are encoded on the short arm of chromosome 6 at locus p21. There are three 
different groups of genes called HLA-A, HLA-B and HLA-C, which individually code for 
the  chain of MHC class I. Similarly, there are three loci for the genes of class II MHC 
molecules known as HLA-DP, HLA-DQ and HLA-DR. Each of these includes genes coding 
for the  polypeptide chain and at least one  polypeptide chain. A person normally inherits 
two copies of the locus of each gene, one from each parent. Statistical data provided by the 
European Bioinformatics Institute (EBI) and the International Immunogenetics Organization 
Database (IMGT) suggest that the number of HLA class I and class II alleles discovered is on 
the increase. These data indicate that in human population there are 4,946 different class I 
alleles and 1,457 class II alleles, of which 1,601 are known alleles for HLA-A, 2,125 for HLA-
B, 1,102 for HLA-C and 1,027 for HLA-DRβ of which 928 are HLA-DRβ1 alleles (these are 
the ones most commonly used to determine histocompatibility due to their high 
polymorphism) (Table 1). 
 
Numbers of HLA Alleles  
HLA Class I Alleles 4,946 
HLA Class II Alleles 1,457 
HLA Alleles 6,403 
  
HLA Class I
Gene A B C E F G  
Alleles 1,601 2,125 1,102 10 22 47  
Proteins 1,176 1,641 808 3 4 15  
 
HLA Class II 
Gene DRA DRB DQA1 DQB1 DPA1 DPB1 DMA DMB DOA DOB 
Alleles 7 1,027 44 153 32 149 7 13 12 13 
Proteins 2 774 27 106 16 129 4 7 3 5 
 
HLA Class II- DRB Alleles 
Gene DRB1 DRB2 DRB3 DRB4 DRB5 DRB6 DRB7 DRB8 DRB9  
Alleles 928 1 57 15 19 3 2 1 1  
Proteins 704 0 46 8 16 0 0 0 0  
(Modified from http://www.ebi.ac.uk/imgt/hla/stats.html) 
Table 1. Statistical data from the European Bioinformatics Institute (EBI) and the 
International Immunogenetics Organization database (IMGT) showing the number of each 
of the HLA alleles. 
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Historically, HLA immunotyping was performed by serological methods but now, with the 
advent of polymerase chain reaction (PCR), molecular immunotyping of the donor and 
recipient is possible. A study by Petersdorf et al. in 2001 examined patients who had 
previously undergone transplantation and were compatible by serological methods. When 
reexamined by molecular immunotyping, about 30%of these individuals were found to be 
incompatible in one or more alleles. These differences were correlated with increased GVHD 
and poor survival, indicating that a compatible donor and reliable HLA immunotyping are 
extremely important. The number of class I and class II HLA antigens is relatively large and 
therefore the probability of HLA matching between the recipient and an unrelated donor is 
extremely small. 
2.4 Graft-versus-host disease and Th1/Th2/Th17 cytokines 
Graft-versus-host disease (GVHD) may develop after hematopoietic stem cell 
transplantation. It is a reaction of immune cells from the donor against tissues of the host. 
Damage induced on epithelial cells of the host by activated T cells occurs after an 
inflammatory cascade that is unleashed by the conditioning regimen. Approximately 35-
50%of allogenic hematopoietic cell transplantation recipients develop GVHD. The risk of 
developing the disease depends on several factors, primarily the stem cell source and donor 
cytokines, patient age, existing conditions and GVHD prophylaxis. GVHD involves mainly 
the skin, liver and gastrointestinal tract. Despite GVHD-related morbility and mortality, its 
development is often desirable since it has been found to be associated with a lower 
recurrence of malignant disease, in other words, it is important for establishment of the 
graft-versus-tumor effect (Ferrara & Levine, 2008; Léger & Nevill, 2004; Saliba et al., 2007; 
Weisdorf 2007). 
The physiopathology of acute GVHD described by Ferrara & Levine (2008) is a three-stage 
phenomenon. The initial stage involves damage to tissues of the host due to inflammation 
derived from chemo- and/or radiotherapy during the recipient conditioning. In the second 
stage, antigen-presenting cells (APC) of both donor and recipient as well as inflammatory 
cytokines unleash the activation of donor-derived T cells, with expansion and differentiation 
of the latter into effector cells. Antigens (Ag) of the minor histocompatibility complex have a 
central role in this activation. The pathway of T-cell activation results in activation of genes 
coding for cytokines such as IL-2 and interferon gamma (IFN). Cells that produce these 
cytokines are considered to be Th1 profile, as opposed to cells producing predominantly IL-
4, IL-5, IL-10 and IL-13 which are considered to be Th2 phenotype and are assumed to be the 
ones that modulate GVHD. During the third stage, also known as the effector stage, donor-
derived activated T cells mediate cytotoxicity against target cells of the recipient through 
FasL-Fas, perforin and granzyme B interactions as well as additional production of tumor 
necrosis factor  (TNF). This cytokine is produced by monocytes and macrophages, and 
secondarily by T lymphocytes and natural killer (NK) cells (Figure 2). (Ferrara & Levine, 
2008; Jacobsohn & Vogelsang, 2007; Socie & Blazar 2009). 
TNF is firmly involved in GVHD physiopathology at several steps of the process including 
induction of apoptosis in target tissues through the TNF receptor. It also induces the 
activation of macrophages, neutrophils, eosinophils, and B and T cells; stimulates 
production of inflammatory cytokines such as IL-1, IL-6, IL-12 and TNF itself; increases the 
expression of HLA molecules; and promotes lysis by T lymphocytes. High levels of TNF 
are associated with a higher incidence of GVHD in bone marrow transplant recipients. This 
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allogeneic dysregulation, in addition to dysregulation of cytokines, leads to the acute tissue 
damage produced by GVHD.  
 
 
Fig. 2. Physiopathology of graft-versus-host disease. (I) Damage to host tissues by 
inflammation derived from the chemotherapy and/or radiotherapy conditioning regimen. 
(II) Antigen-presenting cells (APC) of both donor and recipient as well as inflammatory 
cytokines unleash the activation of donor-derived T cells, with expansion and differentiation 
of the latter into effector cells. The pathway of T-cell activation results in activation of the 
genes coding for cytokines such as IL-2 and IFN. (III) Effector stage: donor-derived 
activated T cells mediate cytotoxicity against target cells of the recipient through FasL-Fas, 
perforin and granzyme B interactions as well as additional production of tumor necrosis 
factor  (TNF) (Modified from Ferrara & Levine, 2008). 
In our laboratory, we have studied patients who underwent allogenic hematopoietic cell 
transplantation and developed GVHD, finding a correlation between these patients and an 
increased of CD14+ TNF+ cells. Up to 32% of CD14+ cells secreting TNF were found in a 
patient with stage II GVHD, increasing to 47% when the patient progressed to stage III, 
while in patients who did not develop GVHD this behavior was not observed. In patients 
with GVHD development, TNF may promote increased expression of adhesion molecules 
such as VCAM-1, ICAM-1 and E-selectin in endothelium, therefore also promoting 
diapedesis of leukocytes in affected areas and degranulation of these cells with subsequent 
damage to tissues in which they are infiltrated (Aggarwal et al., 2000). On the other hand, 
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activation of endothelium, release of nitric oxide, vasodilation and increased vascular 
permeability, and blood platelet activation are also promoted and, most importantly, 
increased expression of MHC-I and MHC-II molecules as well as co-stimulatory molecules 
such as CD40, CD80 and CD86 in dendritic cells, thus also activating T lymphocytes and 
giving rise to more effective antigen presentation, and along with this, more effective 
allorecognition (Steinman et al., 1998). 
In addition to this, TNF has a major role in the promotion of apoptosis (De Freitas et al., 
2004) and due to the previously mentioned properties, TNF overexpression contributes to 
GVHD emergence and severity (Figure 3). Recent studies reveal an increase not only in 
TNF levels but also in TNF receptors (TNFR1 and TNFR2), and the latter are more stable 
and easier to quantify (Choi et al., 2009; Kitko et al., 2008). 
The role of other cytokines such as those of the Th1 profile is worth noting. Diverse research 
groups initially correlated this profile with GVHD emergence, since large quantities of 
cytokines such as IFN, IL-2 and IL-12 were found in patients with GVHD development and 
this is correlated with GVHD severity (Das et al., 2001; Ju et al., 2005). However, these 
cytokines have a controversial role as they are necessary for development of both GVHD 
and the graft-versus-leukemia effect. We have found that mononuclear cells from patients 
with GVHD development in co-culture secrete large amounts of IFN and IL-2, but we have 
also observed that the capacity of these cells to secrete these cytokines is correlated with 
graft success unaccompanied by relapse or development of infections by opportunistic 
microorganisms, which tells us these cytokines have a dual role. Regarding the significance 
of the Th2 cytokine profile in GVHD control, some study teams point to the overexpression 
of IL-4, IL-5 and IL-10 as a positive prognostic factor (Das et al., 2001; Ju et al., 2005). In our 
laboratory, however, a correlation has been observed only between the overexpression of IL-
10 by mononuclear cells of patients and control of GVHD. 
There are new lymphocyte subsets to which great significance has been ascribed in 
inflammatory processes as well as in many pathologies previously thought to be associated 
with the Th1 profile. The subpopulation of Th17 cells discovered in 2005 is now known to 
have a controversial role as they are implicated in rejection of solid organ grafts (Kappel et 
al., 2008; Carlson 2009; Coghill et al., 2010). 
In murine models, differences in GVHD development have been found between mice that 
were transferred CD4+ IL-17-/- T cells and mice that were transferred normal CD4+ cells. In 
the former, GVHD development took longer. However, no significant differences were 
noted between these groups in relation to mortality due to GVHD or in graft-versus-tumor 
activity. Another major finding was the fact that mice that were transferred CD4+ IL17-/- 
cells had fewer Th1 cells during early stages of GVHD. Also, a reduction occurred in the 
number of IFN-secreting macrophages and granulocytes as well as a decrease in the 
amount of pro-inflammatory cytokines. IL-17 is therefore believed to be essential for GVHD 
development and graft-versus-leukemia activity as it promotes pro-inflammatory cytokine 
production – all this in murine models (Kappel et al., 2008). These data and others showing 
the importance of the Th17 profile in inflammatory processes made several researchers think 
that this profile might be involved in GVHD development and severity in humans (Coghill, 
2011). Our study team recently found that the Th17 profile is not relevant for GVHD 
development. We conducted a pilot study on the importance of this profile in six patients 
who underwent allogenic hematopoietic cell transplantation, following them for six months. 
This group was divided into patients with GVHD development and patients without 
GVHD. Peripheral blood and mononuclear cell cultures were analyzed at 30, 60, 100 and 180 
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Fig. 3. The role of TNF in GVHD emergence and exacerbation.  
days after transplantation. Overproduction of Th17 profile was not observed neither in 
patients with GVHD nor in individuals without GVHD, as opposed to its production in 
healthy volunteers and in a patient who received a syngeneic transplant. Few months after 
concluding our study, Broady et al. (2010) published a similar study on patients who 
underwent allogenic hematopoietic cell transplantation, in which they evaluated Th1 and 
Th17 cells in tissue and peripheral blood in a cohort of 34 patients, of which 20 developed 
acute GVHD and 14 did not develop GVHD. The authors did not find an increase in the 
number of Th17 cells in patients with acute cutaneous GVHD as compared to healthy 
donors, but they did detect increased production of IFN-secreting cells (Broady, 2010). 
GVHD diagnosis is suspected when the recipient develops all or some of the signs and 
symptoms that are characteristic of this disease such as dermatitis (rash), epidermal 
blistering, stomach cramps, abdominal pain with or without diarrhea which may be 
accompanied by passage of blood, nausea, persistent vomiting, and hepatitis (elevated 
bilirubins and/or liver enzymes). Typically, these signs and symptoms occur 100 days after 
allogenic hematopoietic cell transplantation but may also appear later. Because many of 
them are not specific of this complication, diagnosis must be supported with suitable 
biopsies, particularly if the symptoms are atypical or involve only the liver or 
gastrointestinal tract, since histological confirmation is extremely useful. A further reason 
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for biopsy-taking is to help differentiate GVHD from other diseases with similar symptoms, 
such as viral infections or reactions to pharmaceutical agents (Ferrara & Levine 2008; 
Jacobsohn & Vogelsang, 2007). 
In GVHD, mature T cells of the donor that accompany the graft attack host tissues, 
particularly the skin, liver and gastrointestinal tract. This explains the signs and symptoms 
that characterize this disease. To prevent GVHD development, all patients receive some 
type of prophylaxis with immunosuppressors and in some cases T cell depletion , being one 
of the most commonly used methods although its effectiveness has not been fully proven 
since T-cell elimination contributes to absence of GVHD development but patients die from 
relapse because lack of GVT effect. Another prophylactic method involves pharmacological 
treatment with agents that affect T-cell function. These types of prophylaxis elicit adverse 
effects since mature T cells of the donor have a major role in mediating the reconstitution of 
the adaptive immune system, particularly in adults with low thymus function (Jacobsohn & 
Vogelsang, 2007). 
GVHD is classified according to the number and extent of the organs involved (Table 2). In 
the current classification system, established in 1994, GVHD is divided into four groups (I – 
IV). Skin damage is evaluated by the percentage of the body surface area involved, liver 
damage by elevated bilirubins, and gastrointestinal tract damage by the amount of diarrhea 
(Jacobsohn & Vogelsang, 2007; Vela-Ojeda et al., 2008). 
 
Stage Skin Liver 
(bilirubin) 
Gut (stool output/day) 
0 No GVHD rash < 2 mg/dl < 500 ml/day or 
persistent nausea 
1 Maculopapular rash < 25% BSA 2-3 mg/dl 500-999 ml/day 
2 Maculopapular rash < 25 - 50% 
BSA 
3.1-6 mg/dl 1000-1500 ml/day 
3 Maculopapular rash > 50% BSA 6.1-15 mg/dl Adult: >1500 ml/day 
4 Generalized erythroderma plus 
bullous formation 
>15 mg/dl Severe abdominal pain 
with or without ileus 
Grade 
I Stage 1-2 None None 
II Stage 3 or Stage 1 or Stage 1 
III - Stage 2-3 or Stage 2-4 
IV Stage 4 or Stage 4 - 
(Modified from Jacobsohn & Volgelsang 2007). 
Table 2. Classification of acute graft-versus-host disease. 
Chronic GVHD (cGVHD) is one of the most common and significant problems affecting 
recipients of allogenic hematopoietic cell transplantation at long term. It appears 
approximately 100 days after allogenic hematopoietic cell transplantation, which is the 
critical time at which close to 50% of patients develop some degree of cGVHD. Increased use 
of hematopoietic stem cells obtained from peripheral blood rather than bone marrow, 
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increased age of recipients, and the use of busulfan in the conditioning regimen have led to 
a higher incidence of cGVHD. Other clinical risk factors for cGVHD development include 
previous acute graft-versus-host disease (aGVHD) and a second transplant. cGVHD most 
commonly affects the skin, liver, eyes and mouth, although other sites may also be affected. 
Death from severe cGVHD is generally a result of infectious complications. The standard 
treatment for severe cGVHD is a combination of cyclosporine and prednisone. An 
alternating daily regimen of these two agents prolongs survival and reduces drug-related 
adverse effects. Topical therapy in affected areas is recommended for patients with grade 1-2 
cutaneous disease. Survival at 10 years in patients who develop light aGVHD is 
approximately 80%, but it is drastically reduced in patients with severe cGVHD, in whom 
this rate is reported to be 5% (Horwitz & Sullivan 2006; Lee 2005; Vela-Ojeda et al., 2008). 
Alloreactivity is the basis for cGVHD pathogenesis. However, the exact phenotype and 
the origin of alloreactive cells remain somewhat ambiguous. Donor-derived alloreactive 
T-cells transplanted with hematopoietic stem cells play a key role in acute and chronic 
GVHD. Current animal models of cGVHD implicate Th2 cells as the first cell type to 
induce damage. However, in humans with cGVHD, Th1/Th2-polarized CD4+ cells have 
alloreactive properties. The formation of antibodies has been observed in experimental 
models and clinical studies of cGVHD. This suggests that B cells are implicated in the 
physiopathology of cGVHD as shown by antibody production in allogenic hematopoietic 
cell transplantation patients with donor of different sex, since antibodies against minor 
histocompatibility antigens are encoded in the Y chromosome. The presence of anti-
nuclear, anti-double strand DNA and anti-smooth muscle antibodies in a frequency range 
of 11-62% has also been detected in patients with cGVHD as well as the presence of anti-
cytoskeletal and anti-nucleolar antibodies. However, despite these findings, the role of 
antibodies in cGVHD remains unclear (Horwitz & Sullivan 2006; Lee 2005; Vela-Ojeda et 
al., 2008). 
cGVHD can be classified according to type of clinical manifestations or extent of the disease. 
Most patients with cGVHD have previously had aGVHD. cGVHD may also be observed 
after achieving control of aGVHD. Similarly, patients may develop cGVHD without a 
previous history of aGVHD (de novo cGVHD). Classification according to the type and 
extent of clinical manifestations is shown in Table 3. 
The International Center for Research on Bone Marrow and Blood Cell Transplantation 
estimates that 50,000 – 60,000 hematopoietic cell transplantations are performed each year 
throughout the world. Bone marrow is the main source of grafts for transplantation in 
children, although peripheral and umbilical cord blood are being increasingly used. 
Between 2004 and 2008 peripheral blood accounted for 27% and umbilical cord blood for 
32% of transplants in patients fewer than 20 years in age. In patients over 20 years the most 
common source for allogenic hematopoietic cell transplantation is peripheral blood. 
Currently, very few adults receive grafts of umbilical cord blood but its use, although 
infrequent, increased 2-4% between 2004 and 2008. Mobilized peripheral blood is the main 
source for autologous transplantation, representing 91% of autotransplantations in children 
and 98% in adults. In recent years the number of hematopoietic cell transplantations, both 
allogeneic and autologous, in patients over 50 years old has increased. Approximately 40% 
of allogeneic transplants are unrelated donor transplantations. There has been a change 
lately: before 2002 the most commonly used source of hematopoietic stem cells was bone 
marrow but its use has declined since 2003 and peripheral and umbilical cord blood have 
been increasingly used.  
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Classification of GVHD 
Limited chronic GVHD  
Either or both:  
1 Localized skin involvement 
2 Hepatic dysfunction due to chronic GVHD 
Extensive chronic GVHD  
Either:  
1 Generalized skin involvement, or 
2 Localized skin involvement and/or hepatic dysfunction 
due to chronic GVHD 
Plus:  
3a Liver histology showing chronic aggressive hepatitis, 
bridging necrosis, or cirrhosis, or 
b Involvement of eye (Schirmer test with <5-mm wetting), 
or 
c Involvement of minor salivary glands or oral mucosa 
demonstrated on labial biopsy, or 
d Involvement of any other target organ 
Table 3. Classification of chronic graft-versus-host disease (Horwitz & Sullivan, 2006) 
The most common cause of death after allogenic hematopoietic cell transplantation is 
relapse, although in unrelated donor transplants it is followed by GVHD and in HLA-
matched sibling transplants by death from infections. Another major cause of death is 
interstitial pneumonitis (Pasquini & Wang, 2007). 
2.5 Graft-versus-tumor effect 
Existence of the graft-versus-tumor effect was first suggested in 1956 by Barnes et al., upon 
noting eradication of leukemia in irradiated mice receiving allogeneic bone marrow 
transplants, but not in those that after irradiation received syngeneic bone marrow 
transplants. The first evidence of this also occurring in humans came from studies reporting 
that the incidence of relapse was markedly lower in patients who developed GVHD than in 
those who did not (as cited in Appelbaum, 2001), and that just as in murine models, human 
allogenic hematopoietic cell transplantation recipients were at lower risk of relapse than 
recipients of syngeneic stem cell transplantations or allogenic hematopoietic cell 
transplantations in which T cells are previously depleted. Male patients receiving allogenic 
hematopoietic cell transplantation grafts from female donors are also seen to be a special 
group in that donor-derived T cells specific for receptors of minor histocompatibility 
antigens may contribute to development of the graft-versus-tumor or the graft-versus-
leukemia effect as well as GVHD since the graft-versus-leukemia effect is associated with 
presence of GVHD. The potential impact of the graft-versus-leukemia effect can be observed 
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when the patient is administered infusions of donor-derived lymphocytes. Graft versus 
tumor effect formed the basis of the so-called non-myeloablative transplants in which 
intensive chemotherapy regimen are substituted by the antitumoral effect of lymphocytes 
(Jacobsohn & Vogelsang, 2007). 
Factors inducing GVHD or the graft-versus-leukemia effect are not well defined and may to 
some extent be considered speculative. Minor histocompatibility antigens have been 
suggested to play a key role since some of them have limited expression in hematopoietic 
cells, including leukemic cells. These antigens are perhaps targeted by the selective effect of 
the graft-versus-leukemia effect while minor histocompatibility antigens that are expressed 
in general may be targeted by GVHD, but this is still not firmly established (Jacobsohn & 
Vogelsang 2007; Kolb, 2008; Riddell & Appelbaum, 2007). 
Various minor histocompatibility antigens are encoded in Y-chromosome genes that exhibit 
significant polymorphism with their homologues genes of the X chromosome. The former 
genes are responsible for the immune reactions occurring between men and women. 
Differential expression of the genes encoding for minor histocompatibility antigens in 
tissues has been proposed for potential use as a basis to separate the graft-versus-leukemia 
effect from GVHD. Cells that recognize minor histocompatibility antigens which are 
expressed only in hematopoietic cell receptors, including leukemic cells, may have a major 
role in the elimination of the latter without GVHD development. Several minor 
histocompatibility antigens such as HA-1, HA-2, HB-1 and BCL2A1 are expressed by 
hematopoietic cells and are therefore being examined as potential targets in order to 
promote the graft-versus-leukemia effect (Randolph et al., 2004; Kolb, 2008). 
2.6 Clinical relevance of regulation and induction of tolerance after allogenic 
hematopoietic cell transplantation 
The potential benefits of allogenic hematopoietic cell transplantation are offset by the 
moderate survival rate of the graft at long term. This is to a large extent due to 
immunosuppressant agents that unspecifically inhibit immune response in order to prevent 
rejection, but bring multiple adverse effects which are responsible for chronic rejection. 
Therefore, one of the major goals of allogenic hematopoietic cell transplantation is to achieve 
absence of immune response in the face of donor-derived alloantigens without requiring 
prolonged administration of immunosuppressants and to promote the graft-versus-
leukemia effect. To this end, research has focused on the study of regulatory T cells (Treg), 
particularly those of the CD4+CD25highFoxP3+ phenotype (natural Treg, nTreg) as they 
have been shown to be able to control immune response in the face of donor-derived 
alloantigens and therefore possess great potential to establish in vivo tolerance to the 
transplant. These cells have been studied the most but are not the only ones described as 
having a regulatory role since regulatory functions have also been observed in other 
subpopulations of CD4+ cells, in T CD8+ cells, T cells, NK cells and CD3+CD4-CD8-
CD16+56+ cells, also known as NKT cells. The latter have been shown to have a powerful 
anti-tumoral effect and are important in the maintenance of tolerance. This is why many 
studies are focusing on transfer of these cells. The strategy that is being sought for use in the 
near future is ex vivo stimulation of Treg purified with alloantigens of the donor or even 
FoxP3-mediated transfection of alloreactive CD4+CD25¯ cells (Bryceson & Ljunggren, 2007; 
Fehérvari & Sakaguchi, 2005). 
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Natural regulatory T cells (nTreg) express from the time of their differentiation in the 
thymus, CD4+, CD25+ and FoxP3 (forkhead box P3 transcription factor) expression patterns. 
They were identified by Sakaguchi et al. (1995) as a natural subset of CD4+ T lymphocytes 
(approximately 5-10% of the T lymphocytes present in peripheral blood) that 
constitutively express the CD25 molecule and suppress the response of effector T 
lymphocytes (CD4+ and CD8+) in vivo. Another lymphocyte subpopulation in peripheral 
blood are CD4+CD25¯ cells, which through the action of TGF- and IL-2 may come  
to express CD25 and FoxP3, and are known as induced Treg (iTreg). Treg lymphocytes  
are also associated with low expression of CD127 which is positively correlated  
with regulatory function acquisition and negatively correlated with expression of  
FoxP3 (Curiel et al., 2004, Horwitz et al., 2008; Korn 2009; Liu et al., 2006; Seddiki et al.,  
2006). 
CD4+CD25+FoxP3+ Treg cells have a key role in the maintenance of peripheral tolerance, 
and Treg deficiencies give rise to progressive autoimmune disorders. Similarly, improved 
Treg function can prevent graft rejection and suppress tumor immunity. In other words, 
an adequate balance between Treg and effector T cells is essential for maintenance of 
tolerance. In the context of allogenic hematopoietic cell transplantation, Treg have also 
been shown to have a major role in the establishment of tolerance between tissues of the 
recipient and donor-derived immunity. This was initially shown to occur in murine 
models where Treg depletion in the stem cell graft produced increased in GVHD and 
increased Treg numbers resulted in suppression of GVHD after transplantation (Lee 
2005). In humans, patients with active cGVHD are reported to have a lower frequency of 
Treg than patients without cGVHD. These findings suggest that robust reconstitution of 
Treg post-allogenic hematopoietic cell transplantation is required to establish immune 
balance in order to be able to maintain adequate levels of peripheral tolerance. However, 
the mechanisms responsible for Treg reconstitution post-allogenic hematopoietic cell 
transplantation have not been adequately characterized and the factors contributing to 
inadequate recovery of Treg in patients who develop cGVHD are unknown (Matsuoka 
2010). 
Based on data obtained by Matsuoka et al. (2010) in patients examined during the first year 
after allogenic hematopoietic cell transplantation, thymus-dependent generation of Treg 
was considerably affected, but this subpopulation maintained high levels of cell 
proliferation in comparison to constitutive T cells. Such in vivo proliferation is apparently 
driven mainly by lymphopenia of CD4 cells. Among other findings, this study team has also 
shown that high levels of Treg proliferation were offset by higher susceptibility to apoptosis. 
Depletion of Treg in periphery in these patients was associated with development of 
extensive cGVHD. 
On the other hand and in reference to lymphocyte populations that may take part in 
development of tolerance to alloantigens, the subpopulation of CD8+ Treg has been recently 
characterized. These lymphocytes, despite a long history in the field of immunology as 
described by Gershon & Kondo in 1970, have been difficult to characterize, and this factor 
combined with the discovery of CD4 Treg by Hall et al. (1990) and Sakaguchi et al. (1995) 
have considerably limited this area. The importance of CD8 Treg lies in the regulatory role 
observed in experimental autoimmune encephalitis (Lu & Cantor, 2008; Wang & Alexander 
2009; Zheng et al., 2004). 
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The latter subpopulation has been said to be increased in peripheral blood analyses and 
infiltrated tissue of patients with colorectal cancer. Increased expression of TGF-β has also 
been found in these lymphocytes as compared to samples from healthy donors. These cells 
were able to suppress CD4+CD25- cell proliferation and cytokine Th1 production. The paper 
mentions the significance of immunological vigilance and the fact that CD8 Treg may 
promote tumoral growth. It also describes this cell subpopulation in patients with multiple 
sclerosis in whom lower numbers of these cells were correlated with relapse, a fact that may 
evidence their immunosuppressant role in the control of autoimmune diseases (Giovanni 
Frisullo, 2010; Chaput, 2009; Kiniwa, 2007). 
Recently described populations of CD8+ Treg include CD8+ IL-10+ cells present in ovarian 
carcinoma, which are induced by plasmocytoid dendritic cells infiltrating the tumor. This 
differentiation towards CD8+ Treg was shown to be independent of CD4+ Treg. All these 
antecedents combined with the generation of CD8+ Treg through continuous antigen 
stimulation may indicate the importance of the latter in GVHD control. 
3. Conclusions 
TNF levels have a major role in development and severity of graft-versus-host disease and 
can be used as a negative prognostic factor. 
Th1 response is essential and required in post-transplant patients to prevent relapse, graft 
loss and appearance of infections caused by opportunistic microorganisms. 
The Th17 profile has no essential role in development or severity of GVHD and is therefore 
not a target for therapy in these patients. 
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